What is Revvity's life sciences — goodwill?

Revvity (RVTY) reported life sciences — goodwill of $4.75B in Q1 2026.

How has Revvity's life sciences — goodwill changed year-over-year?

Revvity's life sciences — goodwill increased by 3.9% year-over-year, from $4.58B to $4.75B.

What does life sciences — goodwill mean?

This represents the premium paid over the fair value of net identifiable assets during business acquisitions within the Life Sciences segment. It reflects the value of intangible assets such as brand reputation, customer relationships, and proprietary technology that are not separately identifiable.

Revvity (RVTY) Life Sciences — Goodwill

Screener

Other segment segments

Diagnostics

$1.86B-4.0%

Similar metrics at other companies

DHRLife Sciences — Goodwill

$12.78B-0.8%

ASHLife Sciences — Goodwill

$462M-0.9%

DCILife Sciences Segment — Goodwill

$172.8M+2.2%

TMOLife Sciences Solutions — Goodwill

$14.91B+20.9%

CLVTLife Sciences & Healthcare — Goodwill

$256.1M—

ECLGlobal Life Sciences — Goodwill

$2.5B+1.2%

Other financials

Income statement

See full

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

See full

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

See full

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

See full

Market cap$12.83B+28.7%

Enterprise value$15.91B+28.6%

P/E53.5×+18.6×

P/S4.4×+0.9×

Profitability

See full

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

See full

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed: May 12, 2026, 4:07 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000031791-26-000019

Line item	Life Sciences	Diagnostics	Consolidated
Balance at December 28, 2025	$4,744,962	$1,868,531	$6,613,493
Foreign currency translation	(24,952)	(9,826)	(34,778)
Acquisitions	32,035	—	32,035
Balance at April 5, 2026	$4,752,045	$1,858,705	$6,610,750

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's life sciences — goodwill?: Revvity (RVTY) reported life sciences — goodwill of $4.75B in Q1 2026.
How has Revvity's life sciences — goodwill changed year-over-year?: Revvity's life sciences — goodwill increased by 3.9% year-over-year, from $4.58B to $4.75B.
What does life sciences — goodwill mean?: This represents the premium paid over the fair value of net identifiable assets during business acquisitions within the Life Sciences segment. It reflects the value of intangible assets such as brand reputation, customer relationships, and proprietary technology that are not separately identifiable.